Single-Branched Stent-Graft for Thoracic Aortic Diseases Involving Left Subclavian Artery.

PURPOSE: To assess the clinical benefits and complications of thoracic endovascular aneurysm repair (TEVAR) using a single-branched stent-graft in patients with thoracic aortic diseases (TADs) involving the left subclavian artery (LSA).

METHODS

This retrospective study reviewed patients with TADs involving the LSA treated with TEVAR using a unibody single-branched stent-graft (Castor single-branched stent-graft, Shanghai MicroPort Endovascular (Group) MedTech Co., Ltd.) from November 2017 to May 2021. Clinical follow-ups and computed tomographic angiography (CTA) were conducted at 1 week, 3 months, 6 months, and annually.

RESULTS

A total of 114 patients underwent TEVAR with Castor stent-graft. Among 114 patients, 88 had TBAD, 14 had PAU, 6 had pseudoaneurysms, 3 had TAA, and 2 had IMH. Technical success (defined as successful deployment and patency of all stent segments) was 100%. No mortality, endoleak, stroke, or paraplegia was observed during a mean follow-up of 19.8 months. One case of LSA occlusion (0.9%) was noted at 3-month follow-up, without neurological symptoms.

CONCLUSION

The Castor single-branched stent-graft is effective for treating TADs involving the LSA, with high technical success and no short- or midterm complications. Further research is needed to confirm long-term safety and efficacy.